Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT05325450
Recruiting Not applicable

Optimization of Hearing Performance in the Subject Implanted

NCT05325450 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2023-05-18
Last updated
2026-09-21

Condition(s) studied

Hearing Loss

Investigational drug(s) / intervention(s)

Program AProgram BControl

Program A: Presentation of the sentence to the implant alone

Program B: Presentation of the sentence to the implanted ear, associated for the non-implanted ear

Control: Presentation of the sentences alternately to the most recently implanted ear and both implanted ears at the same time

Study summary

In the past two decades, the selection criteria for cochlear implantation have been greatly relaxed so that about 60-70% of present cochlear implant (CI) candidates have significant residual hearing in their contralateral ear. However, contralateral hearing is often not considered in rehabilitation programs, mainly due to the lack of scientific evidence on the role it may play. The present project aims to better understand the mechanisms of perceptual learning of CI-processed speech after implantation and to develop and test rehabilitation strategies for CI users.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age\>18 * Unilaterally postlingually-deafened adult cochlear implanted candidates (IC-Uni) * Person with almost normal or moderate contralateral hearing ( under 60dB) * Cochlear implanted person whose activation has not yet been performed * Cochlear implanted subjects with bilateral post-lingual profound deafness, who already benefit from a unilateral cochlear implant and candidates to a bilateral cochlear implant * Affiliated to social security Exclusion Criteria: * \- Subjects under juridical protections or tutelage measure * Subjects with associated neurological or neurodegenerative conditions * Significant anatomical changes on CT scan of the temporal bone that may interfere with the insertion of the cochlear implant

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Marx Toulouse France Recruiting

More University Hospital, Toulouse trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05325450 on ClinicalTrials.gov ↗ ← All trials in France